Pulmonary fibrosis 4 months after COVID-19 is associated with severity of illness and blood leucocyte telomere length

Claire F McGroder, David Zhang, Mohammad A Choudhury, Mary M Salvatore, Belinda M D’Souza, Eric A Hoffman, Ying Wei, Matthew R Baldwin, Christine Kim Garcia

ABSTRACT

The risk factors for development of fibrotic-like radiographic abnormalities after severe COVID-19 are incompletely described and the extent to which CT findings correlate with symptoms and physical function after hospitalisation remains unclear. At 4 months after hospitalisation, fibrotic-like patterns were more common in those who underwent mechanical ventilation (72%) than in those who did not (20%). We demonstrate that severity of initial illness, duration of mechanical ventilation, lactate dehydrogenase on admission and leucocyte telomere length are independent risk factors for fibrotic-like radiographic abnormalities. These fibrotic-like changes correlate with lung function, cough and measures of frailty, but not with dyspnoea.

INTRODUCTION

Reports of hospitalised COVID-19 survivors show that there are persistent symptoms, radiographic abnormalities and physiological impairments months after the initial illness. Persistent chest imaging abnormalities and histopathological findings of lung fibrosis were also found in a majority of survivors of the SARS-CoV-1 2003 outbreak, suggesting that the SARS viruses may lead to a worse fibroproliferative response than other pneumonias.

RESULTS

We conducted a single-centre prospective cohort study of adults hospitalised between 1 March 2020 and 15 May 2020 who required supplemental oxygen. At 4 months after hospitalisation, participants underwent a non-contrast high-resolution chest CT (HRCT) scan, pulmonary function testing, measurement of 6-minute walk distance (6MWD), assessment of the frailty phenotype and a blood draw for isolation of genomic DNA. Radiographic patterns were categorised and quantitated using a severity scoring system developed by ARDSnet and used in acute respiratory distress syndrome (ARDS) survivors, and classified into two groups (non-fibrotic or fibrotic). Fibrotic-like patterns included those with reticulations, traction bronchiectasis or honeycombing. Telomere length of genomic DNA isolated from blood drawn at the 4-month follow-up visit was measured by a quantitative PCR assay.

We calculated Spearman’s rank correlation coefficients between continuous data. We created separate generalised additive logistic models (GAMs) to test adjusted associations between the risk of fibrotic-like patterns on CT scan and independent continuous variables identified in univariable analysis. Due to the moderate cohort size and rate of fibrotic-like radiographic abnormalities, we used generalised covariate balanced propensity scores to adjust for potential confounders. We estimated adjusted ORs using logistic regression models if there was no evidence of non-linearity.

METHODS

Additional details are included in the supplemental materials.

We conducted a single-centre prospective cohort study of adults hospitalised between 1 March 2020 and 15 May 2020 who required supplemental oxygen. At 4 months after hospitalisation, participants underwent a non-contrast high-resolution chest CT (HRCT) scan, pulmonary function testing, measurement of 6-minute walk distance (6MWD), assessment of the frailty phenotype and a blood draw for isolation of genomic DNA. Radiographic patterns were categorised and quantitated using a severity scoring system developed by ARDSnet and used in acute respiratory distress syndrome (ARDS) survivors, and classified into two groups (non-fibrotic or fibrotic). Fibrotic-like patterns included those with reticulations, traction bronchiectasis or honeycombing. Telomere length of genomic DNA isolated from blood drawn at the 4-month follow-up visit was measured by a quantitative PCR assay.

We calculated Spearman’s rank correlation coefficients between continuous data. We created separate generalised additive logistic models (GAMs) to test adjusted associations between the risk of fibrotic-like patterns on CT scan and independent continuous variables identified in univariable analysis. Due to the moderate cohort size and rate of fibrotic-like radiographic abnormalities, we used generalised covariate balanced propensity scores to adjust for potential confounders. We estimated adjusted ORs using logistic regression models if there was no evidence of non-linearity.
receptor blockade (online supplemental table S3). Qualitative measures of non-fibrotic and fibrotic patterns as scored by radiologists were closely associated with quantitative scores ascertained by adaptive multiple feature method (AMFM) texture analysis (online supplemental figure S2).

Participants had an array of functional deficits (online supplemental table S5). Overall, 40 (53%) had a reduced diffusion capacity, 78% had a decreased 6MWD, 18% remained >10% below baseline weight and 53% had weak grip strength.

Ground glass, reticulations and traction bronchiectasis scores correlated more strongly with reduction in diffusion capacity ($\rho$ –0.34, –0.64 and −0.49, respectively, all $p<0.01$) than FVC (table 1). Ground glass correlated with the frailty phenotype score, while reticulation and traction bronchiectasis correlated with grip strength and gait speed.

**Table 1** Spearman correlation coefficients of radiographic and dyspnoea scores with pulmonary function, 6-minute walk distance, frailty and symptoms

<table>
<thead>
<tr>
<th>CT pattern</th>
<th>DLCO (% predicted) R2</th>
<th>$r$</th>
<th>P value</th>
<th>FVC (% predicted) R2</th>
<th>$r$</th>
<th>P value</th>
<th>6MWD (m) R2</th>
<th>$r$</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ground glass opacities</td>
<td>0.12</td>
<td>−0.34</td>
<td>0.003*</td>
<td>0.06</td>
<td>−0.25</td>
<td>0.03*</td>
<td>0</td>
<td>−0.02</td>
<td>0.92</td>
</tr>
<tr>
<td>Reticulations</td>
<td>0.41</td>
<td>−0.64</td>
<td>&lt;0.001*</td>
<td>0.04</td>
<td>−0.21</td>
<td>0.07</td>
<td>0</td>
<td>−0.02</td>
<td>0.08</td>
</tr>
<tr>
<td>Traction bronchiectasis</td>
<td>0.24</td>
<td>−0.49</td>
<td>&lt;0.001*</td>
<td>0.05</td>
<td>−0.23</td>
<td>0.04*</td>
<td>0</td>
<td>−0.05</td>
<td>0.69</td>
</tr>
</tbody>
</table>

**Table 1** Continued

<table>
<thead>
<tr>
<th>CT pattern</th>
<th>DLCO (% predicted) R2</th>
<th>$r$</th>
<th>P value</th>
<th>FVC (% predicted) R2</th>
<th>$r$</th>
<th>P value</th>
<th>6MWD (m) R2</th>
<th>$r$</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Frailty phenotype score</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ground glass opacities</td>
<td>0.21</td>
<td>0.46</td>
<td>&lt;0.001*</td>
<td>0</td>
<td>0.07</td>
<td>0.56</td>
<td>0.02</td>
<td>0.14</td>
<td>0.23</td>
</tr>
<tr>
<td>Reticulations</td>
<td>0.05</td>
<td>0.23</td>
<td>0.04*</td>
<td>0.07</td>
<td>0.26</td>
<td>0.02*</td>
<td>0</td>
<td>0.05</td>
<td>0.66</td>
</tr>
<tr>
<td>Traction bronchiectasis</td>
<td>0.03</td>
<td>0.16</td>
<td>0.17</td>
<td>0.06</td>
<td>0.25</td>
<td>0.03*</td>
<td>0</td>
<td>0.07</td>
<td>0.57</td>
</tr>
</tbody>
</table>

**Table 1** Continued

<table>
<thead>
<tr>
<th>CT pattern</th>
<th>DLCO (% predicted) R2</th>
<th>$r$</th>
<th>P value</th>
<th>FVC (% predicted) R2</th>
<th>$r$</th>
<th>P value</th>
<th>6MWD (m) R2</th>
<th>$r$</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>UCSD SOBQ</td>
<td>0.02</td>
<td>−0.14</td>
<td>0.24</td>
<td>0.06</td>
<td>−0.25</td>
<td>0.04*</td>
<td>0.06</td>
<td>−0.25</td>
<td>0.03*</td>
</tr>
</tbody>
</table>

**Table 1** Continued

<table>
<thead>
<tr>
<th>CT pattern</th>
<th>DLCO (% predicted) R2</th>
<th>$r$</th>
<th>P value</th>
<th>FVC (% predicted) R2</th>
<th>$r$</th>
<th>P value</th>
<th>6MWD (m) R2</th>
<th>$r$</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>UCSD SOBQ</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Significant after controlling for false discovery using the Benjamini-Hochberg method at a false discovery rate of 0.10.

DLCO, diffusion capacity for carbon monoxide; 6MWD, 6-minute walk distance; UCSD SOBQ, University of California San Diego Shortness of Breath Questionnaire.

Figure 1  High-resolution CT (HRCT) scans of the chest from COVID-19 survivors. (A) Representative CT chest scans demonstrating no abnormalities (left), non-fibrotic patterns (middle) and fibrotic-like patterns (right). The upper panels show a coronal section and the lower panels show an axial image at the level just below the carina. The scan with a non-fibrotic pattern had a ground glass opacities (GGO) score of 5.6 (84th percentile in the group). The CT scan with a fibrotic-like pattern had a reticulation score of 6.4 (98th percentile), a traction bronchiectasis score of 5.0 (95th percentile) and no honeycombing. (B) Chest HRCT scores for radiographic patterns observed in the study cohort. The middle line of the boxplot represents the median score; bottom and top lines represent the 25th and 75th percentile, respectively. Where no lines are seen, the 25th, 50th and 75th percentile scores were all 0. The extent of each pattern was graded using a scoring system developed by ARDSnet. The possible range of scores was 0–20 from all categories of abnormalities, except traction bronchiectasis, which had a possible range of 0–5.
with cough. Dyspnoea correlated more strongly with markers of weakness and deconditioning, including increased frailty score and reduced grip strength, than radiographic abnormalities (Table 1). Similarly, the 6MWD was associated with the dyspnoea score and not with radiographic abnormalities.

Fully adjusted GAMs showed that both admission SOFA score and percent-predicted telomere length were linearly associated with the predicted risk of fibrotic-like radiographic abnormalities (Figure 2). Duration of mechanical ventilation varied linearly with the predicted risk of fibrotic-like patterns through 20 days and plateaued with more prolonged mechanical ventilation. LDH levels also plateaued at higher levels. In fully adjusted logistic regression models, every 1-point increase in SOFA score, 50-point increase in LDH and 1 ventilator-day was associated with 1.49 (95% CI 1.17 to 1.89), 1.24 (95% CI 1.06 to 1.43) and 1.07 (95% CI 1.03 to 1.12) higher odds of fibrotic-like patterns on CT scan, respectively. Sensitivity analyses are shown in online supplemental figures S3 and S4.

**Figure 2** Continuous associations of fibrotic-like patterns with admission Sequential Organ Failure Assessment (SOFA) score (top left), lactate dehydrogenase (LDH) levels (top right), duration of mechanical ventilation in days (bottom left) and age-adjusted leucocyte telomere length percentile (bottom right) using generalised additive models with locally weighted smoothing (LOESS). Blue line represents predicted values. Black dashed lines are 95% CIs. Hash marks along the x-axis indicate individual study participants. Since there was no evidence for non-linearity in the generalised additive models, we estimated adjusted ORs using logistic regression models. All models are adjusted for a common set of potential confounders (age, sex, race/ethnicity, days since infection, body mass index, pack-years of smoking, treatment with steroids while hospitalised) and the other independent variables of interest (SOFA score, LDH, days of mechanical ventilation, telomere length). OR for SOFA score is per point increase, for LDH is per 50-point increase, for mechanical ventilation is per day increase, and for telomere length is per 10% decrease in percent-predicted value.

**DISCUSSION**

Pulmonary fibrosis is a feared complication of respiratory infections. We found that among survivors of severe COVID-19, 20% of non-mechanically ventilated and 72% of mechanically ventilated individuals had fibrotic-like radiographic abnormalities 4 months after hospitalisation. The presence of these radiographic abnormalities correlates with decrements in lung function, cough and frailty. Greater initial severity of illness, longer duration of mechanical ventilation and shorter blood leucocyte telomere length are independent risk factors for the development of fibrotic-like abnormalities.

Fibrosis was measured in this study both subjectively, in a manner congruent with other population-based, ARDS, SARS-CoV-14 and COVID-191 2 6 10 studies, as well as objectively using texture analysis.11 We include reticulations as a manifestation of fibrotic-like patterns to facilitate comparison to prior post-infectious studies,7 including post-acute COVID-19 studies,2 10 and acknowledge that reticulations may either resolve or progress over time.4 The presence of the pulmonary function degradation associated with these radiographic findings at 4 months is concerning for potential long-term damage. In the absence of longer-term follow-up, it is unclear if these functional and radiographic abnormalities represent permanent lung scarring.

This is the first study to identify age-adjusted telomere length as an independent risk factor for post-COVID lung fibrosis. Short blood leucocyte telomere lengths have been shown to be a risk factor for the development of different subtypes of fibrotic interstitial lung disease, including idiopathic pulmonary fibrosis (IPF).12 Here, we also find that longer telomere lengths appear to be protective, thus, this genomic biomarker may measure the balance of profibrotic and antifibrotic susceptibilities.
Limitations of this study include its small size, the lack of replication cohort and the need to use a propensity score to adjust for covariates. It is possible that acute illness may affect telomere length or that some imaging abnormalities were pre-existing. Patients were hospitalised prior to US Food and Drug Administration (FDA)-approved therapies, yet half received steroids.

This study reveals significant respiratory symptoms and morbidity associated with severe COVID-19. Dyspnoea, reported by many survivors, correlates more strongly with muscle strength and frailty measures than radiographic pattern scores, suggesting persistent extrapulmonary effects, including cardiovascular or neuromuscular dysfunction. Additional prospective studies are needed to characterise temporal changes of post-COVID-19 fibrotic abnormalities, and clinical trials are needed to investigate therapeutic options to promote its resolution.

Twitter Claire F McGroder @Claire_McGroder

Acknowledgements The authors wish to thank the patients for their participation, Deanna D. Rivas and Mason W. Amelotte for excellent technical assistance, Junfeng Guo, PhD, for assistance with the AMFM analysis, and the Safety Monitoring Board (SMB) Chair Joao De Andrade, MD, and SMB members Anil Vachani, MD, and Anna Rozenstein, MD. The study sponsors had no role in data analysis and interpretation, manuscript writing or dissemination of results.

Contributors CM, MRB and CGK conceptualised the study, CM, MAC and MRB recruited patients and collected samples and clinical data. DZ performed experiments and analysed data. MS, BD and EAH analysed imaging studies. CM, DZ, YW, MRB and CGK performed statistical analysis. CM, MRB and CGK wrote the manuscript.

Funding This work was supported by the NIH (R01HL103676, R01HL093096 to CGK; T32HL105323 to CM; UL1TR001873 to MRB) and the Department of Defense (PR202907 to CKG and MRB).

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Matthew R Baldwin http://orcid.org/0000-0003-4670-3433
Christine Kim Garcia http://orcid.org/0000-0002-0771-1249

REFERENCES